Long-term A3-71 Results
Yes, I saw that, too. Stunning, that symptomatic resolution would endure following A3-71 dosing durations (without the drug).
First, we dare not use the word “cure.” Ever. Just too loaded with unprovable traits or difficult substantiation. Would be nice; take A3-71 for six months, go off it, and live many, many more happy years without any Alzheimer’s symptoms.
Doubt that would be the case, however. Whatever first caused the loss of neuron homeostasis; bad foods, other drugs, normal aging, whatever; would still be present and the symptoms would return.
I hold the view that Alzheimer’s and the other CNS diseases Anavex will treat with their new drugs are chronic diseases, similar to type 2 diabetes. Something causes insufficient production or function of insulin, and serum glucose levels elevate, with untoward symptomatic consequences. Administer sufficient insulin, and systematic glucose homeostasis is restored. Stop the insulin, and things go bad again. Gotta take the insulin chronically and persistently to control the diabetes (in most cases).
I see the same with Alzheimer’s, amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease), Parkinson’s, and any number of similar CNS diseases. Once symptoms appear, A2-73 (or, probably better, A3-71) will be prescribed. “Take one of these once every morning after getting out of bed. Forever.”
Of course, contemplate the continuing revenue streams to Anavex should their drugs be so administered. How many Americans are entering or are in old age ranges where CNS diseases proliferate? In a few years, how many daily Anavex dosages will be consumed by aging people in the world — not only to treat emerging symptoms, but as prophylaxis, taken before symptoms appear, to prevent disease onset?
Because of the absence of side effects, either of the new Anavex drugs could be taken chronically, as in the manner of low-dose aspirin.
Imagine the social, financial, and medical outcomes should Anavex drugs both treat and prevent a multitude of geriatric diseases, including cardiovasuclar conditions, cancers, or psychiatric conditions. There are preliminary reports of all of these in murine (rat) lab studies.
